Company news

Radiopharm Theranostics Limited news in 2026

Radiopharm Theranostics Limited's news releases, calls and decks from 2026, newest first.

View company

RAD completes A$12.5 M placement and launches A$6 M SPP

July 24, 2026

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026

RAD Achieves Partial Response in Phase 1 Trial of RAD204

July 21, 2026

Radiopharm Theranostics Reports Business Update

April 23, 2026

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

April 20, 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

April 16, 2026

RAD Completes Enrollment in Phase 2b Trial of RAD 101

April 15, 2026

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

April 8, 2026

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3

April 7, 2026

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

April 7, 2026

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

March 27, 2026

RAD Doses First Patient in RAD 402 Phase 1 Clinical Study

March 26, 2026

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

March 24, 2026

RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint

March 23, 2026

Half Year Report and Appendix 4D 31 December 2025

February 27, 2026

Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

February 25, 2026

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

February 24, 2026

RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study

February 23, 2026

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

January 28, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 27, 2026

Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

January 21, 2026

Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

January 20, 2026

RAD Increases Ownership in Radiopharm Ventures to 87.5%

January 12, 2026

← Newer news releases

Decks in 2026